Compare ARCO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | ANAB |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2011 | 2015 |
| Metric | ARCO | ANAB |
|---|---|---|
| Price | $8.00 | $54.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $8.60 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 1.1M | 403.8K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $12.56 | N/A |
| Revenue Next Year | $3.48 | $52.14 |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $6.54 | $17.11 |
| 52 Week High | $9.75 | $73.30 |
| Indicator | ARCO | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 43.30 |
| Support Level | $7.76 | $53.46 |
| Resistance Level | $8.13 | $57.70 |
| Average True Range (ATR) | 0.19 | 2.42 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 27.78 | 13.88 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Its menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others. It generates maximum revenue from Brazil.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).